All News

Farah Towfic, PharmD, MBA, RPh, explains the importance of USP's expert volunteer recruitment, particularly among pharmacists, to help create public quality standards, promote health literacy, and support initiatives, with applications open until March 13, 2025, for the next strategic cycle beginning July 1, 2025.

Presentations detail clinical trial results and drugs in the pipeline.

Palbociclib is an oral CDK4/6 inhibitor that was approved by the FDA in 2017.

The report from the Office of Inspector General highlights inconsistencies, lack of transparency, and the need for stronger safeguards.

Admissions to the hospital for fever were reduced in pediatric patients with medium-risk ALL receiving intravenous immunoglobulin, a potentially useful finding to help prevent infections in vulnerable patients.

Compared with chemotherapy, Dato-DXd demonstrates favorable median progression-free survival and overall survival in a phase 3 clinical trial.

The FDA proposes to cap the nicotine level at 0.7 mg per gram of tobacco in cigarettes and certain other combusted tobacco products.

If finalized, the requirement would include readily available nutrition information, including saturated fat, sodium, and added sugar content.

The authors note that future research will observe personality changes when psilocybin is used in patients with opioid-use disorder.

Pharmacies are increasingly viewed as wellness hubs and community health partners.

Despite the reductions in hepatitis B surface antigen (HBsAg), grade 3 and 4 adverse events were not uncommon.

These drugs are set to revolutionize their respective disease states in 2025.

Christopher Herndon, PharmD, BCACP, FASHP, FCCP, CPE, discusses the upcoming BPS pain management certification launching in late 2025, its role in validating pharmacist expertise.

Data from the CodeBreaK 300 trial supported the FDA's approval.

Pharmacies are actively working to address issues and support their patients by collaborative with regulatory bodies like the Board of Pharmacy, and their engagement with the local community.

Acalabrutinib with bendamustine and rituximab shows efficacy in patients with untreated mantel cell lymphoma by increasing progression-free survival in the ECHO trial.

As per the Inflation Reduction Act, the negotiations with the drug companies of the 15 drugs will occur in 2025, with the negotiated prices going into effect in 2027.

Hormonal contraceptives did not increase breast cancer risk in patients with BRCA2 mutations.

The current approved dose of axatilimab-csfr is 0.3 mg/kg up to a maximum dose of 35 mg and will be administered as an intravenous infusion over 30 minutes every 2 weeks.

This is mirikizumab’s second FDA-approved indication in inflammatory bowel disease.

Rite Aid survey highlights underutilized role of pharmacists in health care, with 62% of respondents viewing their pharmacists as a crucial part of their health and wellness care team.

A politically and economically stressed system of health care delivery and benefits is manifesting in the pharmacy benefit management sector.

Farah Towfic, PharmD, MBA, RPh, discusses how US Pharmacopeia helped to strengthen supply chain resilience in 2024 through data-driven insights, policy advocacy, and pharmacist engagement to address prolonged drug shortages, particularly for generic sterile injectables.

The combination yields promising results but was associated with high incidence of toxicity and infection.

Pharmacists help patients manage allergies and asthma by identifying triggers, recommending appropriate treatments, ensuring proper medication usage, and finding affordable options.

However, investigators also find that the combination did not meet the primary end point of increasing progression free survival.

The finding could help better treat patients with long COVID, as pharmacists and treatment providers can look out for ME/CFS symptoms.